Startups

Senior Vice President, Head of Corporate Development

Revolution Medicines · Redwood City, California, United States · On-site

← All jobs
About Revolution Medicines

Backed by GV.

About the role

This newly created role is an enterprise leader responsible for shaping and executing Revolution Medicines’ corporate development strategy to advance the company’s long-term strategic, portfolio, and growth objectives. Reporting to the COO, the SVP will lead the identification, evaluation, structuring, negotiation, and execution of strategic transactions that expand the company’s pipeline and capabilities, strengthen its competitive position, and create long-term value for patients and shareholders.

What they're looking for

  • At minimum of 15 years of experience in biotech or pharmaceuticals industry, preferable in oncology, with at least 10 years in business or corporate development leadership roles
  • Advanced degree in a scientific, medical, business, legal, or related discipline preferred, equivalent relevant experience will be considered
  • Demonstrated track record of negotiating and executing complex, high-value strategic transactions, potentially including acquisitions, licensing transactions, collaborations, co-development agreements, investments, and other innovative transaction structures
  • Deep understanding of biopharmaceutical strategy, drug development, commercialization, portfolio management, valuation, and transaction economics
  • Strong strategic and financial acumen with demonstrated ability to evaluate opportunities through both enterprise strategy and capital allocation lenses
  • Exceptional negotiation skills and demonstrated ability to navigate complex transactions involving scientific, clinical, commercial, intellectual property, financial, operational, and legal considerations
More about this role

Revolution Medicines is a global, commercial-state oncology company dedicated to discovering, developing and delivering innovative medicines for patients with RAS-addicted cancers. Leveraging its differentiated RAS(ON) tri-complex inhibitor platform, the company is advancing a broad, integrated portfolio of oral RAS(ON) inhibitors designed to directly target the active, cancer-driving state of RAS. Founded on rigorous scientific inquiry and a willingness to challenge long-held assumptions, Revolution Medicines is committed to changing the trajectory of disease for patients with RAS-addicted cancers worldwide.

Our people are united by a shared way of working: follow the science, challenge assumptions, act with urgency and hold ourselves to a high standard of rigor—all in service of patients.

This newly created role is an enterprise leader responsible for shaping and executing Revolution Medicines’ corporate development strategy to advance the company’s long-term strategic, portfolio, and growth objectives. Reporting to the COO, the SVP will lead the identification, evaluation, structuring, negotiation, and execution of strategic transactions that expand the company’s pipeline and...

Read the full posting on Revolution Medicines's site ↗

Corporate Development

Build your edge while you search

Free tools for founders and investors, plus VC Unfiltered, our take on startups, venture and the people who build them.